Follow us on Twitter
twitter icon@FreshPatents


Osteoporosis patents

      

This page is updated frequently with new Osteoporosis-related patent applications.




 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Fibronectin based scaffold domain proteins that bind to myostatin patent thumbnailFibronectin based scaffold domain proteins that bind to myostatin
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company


 Use of peptidic drugs for osteoporosis treatment and bone regeneration patent thumbnailUse of peptidic drugs for osteoporosis treatment and bone regeneration
The present invention provides osteogenic peptides derived from the cementum-derived attachment protein (hacd1/cap) and another derived from the cementum protein 1 (cemp1) and pharmaceutical compositions of these peptides for the prevention and treatment of osteopenia and osteoporosis. These peptides increase bone mineral density in an osteoporotic model and without in vivo side effects, demonstrating clinical effectiveness in the prevention and treatment of osteopenia and osteoporosis in vivo as well as bone repair and/or regeneration..
Universidad Nacional Autonoma De Mexico


 Furo[3,4-b]pyran compounds and pharmaceutical uses patent thumbnailFuro[3,4-b]pyran compounds and pharmaceutical uses
Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited


 Peptides for preventing or treating bone diseases and use thereof patent thumbnailPeptides for preventing or treating bone diseases and use thereof
The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell.
Kyungpook National University Industry - Academic Cooperation Foundation


 Novel peptides for preventing or treating bone diseases and use thereof patent thumbnailNovel peptides for preventing or treating bone diseases and use thereof
The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell.
Kyungpook National University Industry - Academic Cooperation Foundation


 Compositions and methods for treatment of osteoporosis and other indications patent thumbnailCompositions and methods for treatment of osteoporosis and other indications
The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide.
Transdermal Biotechnology, Inc.


 Selective elimination of erosive cells patent thumbnailSelective elimination of erosive cells
The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-nkg2a antibody..
Novo Nordisk A/s


 Compositions and methods for controlled localized delivery of bone forming therapeutic agents patent thumbnailCompositions and methods for controlled localized delivery of bone forming therapeutic agents
The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture.
University Of Rochester


 Use of organic sulphur, antioxidants, and amino acids in conjunction with exercise and electromagnetic stimulation to treat osteoporosis patent thumbnailUse of organic sulphur, antioxidants, and amino acids in conjunction with exercise and electromagnetic stimulation to treat osteoporosis
Through the use of a combination of naturally occurring substances, application of mechanical energy by way of exercise, and application of a pulsed electromagnetic field (pemf), new bone formation at lines of stress can be promoted. This bone forming activity is useful in the treatment and prevention of osteoporosis.

Calcium supplement having enhanced absorption

Dietary calcium supplements comprising highly bioavailable forms of calcium carbonate and methods of using these calcium carbonate forms to improve calcium balance, strengthen bones, and prevent, treat, and/or ameliorate bone loss associated with osteoporosis are provided.. .
Delavau Llc

Oxazolidine-based compound and selective androgen receptor agonist comprising same

Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc..
Dong-a St Co., Ltd.

Inhibitor of inflammatory conditions

The invention relates to boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: inflammatory bowel disease (ibd), all forms of muscular dystrophy especially duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. Host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, alzheimer's disease, demyelinating neurological disorders including multiple sclerosis, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders..
Compton Developments Ltd.

Isoform nell-1 peptide

This application is drawn to a method of using an isoform nell-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis.. .
The Regents Of The University Of California

Method for preparing osteoblasts and osteoblast inducer

An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) camp inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts..
Kyoto Prefectural Public University Corporation

Pparg modulators for treatment of osteoporosis

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, paget's disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist pparg modulator to a patient afflicted with the disease.. .
University Of Toledo

Irisin for care and prevention of osteoporosis

Object of the present invention is the use of irisin for the treatment and/or prevention of osteoporosis. In particular, the present invention refers to the use of recombinant irisin for the treatment and/or prevention of osteoporosis..
Universita' Politecnica Delle Marche

Tumor eradication by inositol-tripyrophosphate

The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the above salts in an effective amount in individuals for the treatment of various types of cancers, alzheimer's disease, stroke and osteoporosis..
Normoxys, Inc.

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Novel forms of [r, (r*,r*)]-2-(4-fluorophenyl)-β,δdihydroxy-5-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, forms xxv, form xxvii, form xxviii, form xxxix, and forms xxx, characterized by their x-ray powder diffractor, solid state nmr, and/or raman spectroscopy are describes as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer) disease.. .
Warner-lambert Company Llc

Red light implants for treating osteoporosis

A method of irradiating spinal tissue with red/nir light, comprising: inserting a cannulated device defining a bore into the spinal column, wherein the bore contains an optically transparent substrate adapted to emit red/nir light, and transmitting nir/red light through the substrate to irradiate tissue within the spinal column.. .
Depuy Synthes Products, Inc.

Citrate-rich calcium-magnesium supplement and uses thereof

Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors..
The Board Of Regents Of The University Of Texas System

Amphiphilic peptide matrices for treatment of osteoporosis

The present invention provides methods for prevention, prevention of progression, and treatment of osteoporosis and pre-osteoporotic conditions comprising direct administering to osteoporotic bone of a composition comprising amphiphilic peptides and peptide matrices thereof, useful in promoting biomineralization, local osteoporotic medications and inducing bone repair.. .
Ben-gurion University Of The Negev Research And Development Authority

Bone and joint protection composition and use thereof

The invention relates to a bone and joint protection composition and use thereof. According to the composition, the four chinese medicinal herbs eucommiae cortex, achyranthis bidentatae radix, astragali radix and chuanxiong rhizoma are used, and the effects of enhancing the bone density, preventing and relieving osteoporosis, restraining the activity of osteoclast, promoting the function of bone cells, increasing the formation of calcified bone, promoting cartilage repair, delaying joint recession and repairing joint damage are achieved through multiple approaches and multiple levels.
Infinitus (china) Company Ltd.

Novel cannabinoid receptor 2 (cb2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases

Wherein: r1 and r2 are independently h, alkyl, or alkenyl; r3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; r4 and r5 are independently a bond, alkylenyl, or alkenylenyl; each r6 and r7 is independently selected from the group consisting of oh, f, cl, br, i, (c1-c6)alkyl, alkoxy, amino, cooh, conh2, so3h, po3h2, cn, sh, no2 and cf3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma..

Topical composition with vitamin d3

The topical composition with vitamin d3 includes vitamin d3, one or more aromatic oils, and aloe vera gel. Vitamin d3 is soluble in aromatic oils, and aloe vera gel enables transport through the stratum corneum so that the composition may be used for fulfilling daily requirements, treatment of bone conditions, such as rickets and osteomalacia, and supportive therapy in osteopenia and osteoporosis.

Ron inhibitors for use in preventing and treating bone loss

Provided herein are methods for inhibiting osteolysis or treating osteoporosis in a subject in need thereof, the method including administering to the subject at least one ron inhibitor. The osteolysis may be caused by a condition selected from the group consisting of cancer, inflammation, and cyst.
University Of Utah Research Foundation

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis..
Merck Sharp & Dohme Corp.

Composition for preventing and healing compromised bone and a making same

A biologically active additive composition for preventing and healing bone diseases comprises a pharmacologically active compound of calcium chosen from a series comprising calcium carbonate, calcium citrate, calcium gluconate, calcium aspartate, calcium amino acid chelate, calcium fumarate, calcium succinate, calcium ascorbate, calcium phosphate, or any combination thereof, in the amount of 16.67-93.75 weight %, and drone brood in the amount of 6.25-83.33 weight %. Due to the combination, osteoporosis, bone fractures and cavities, arthritis, arthrosis, paradontosis can be prevented and healed with substantially reduced risk of calcium deposition in soft tissues.

Use of compounds that are able to increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced igf-1 serum level in humans and animals

The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (igf-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise.
Veijlen N.v.

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.

Composition for preventing or treating osteoporosis, containing progranulin inhibitor as active ingredient

Disclosed is a composition for inducing the differentiation of osteoclasts containing progranulin as an active ingredient, or a composition for the prevention or treatment of osteoporosis containing a progranulin inhibitor as an active ingredient, wherein progranulin functions as an rank-dependent cell-communication factor and as a mediator in osteoporosis through inflammation, and exists at a remarkably high concentration, compared to a control, in the serum of prostate cancer patients, osteoporosis patients, and bedridden patients with low bone mineral density, whereby the progranulin can be used as an osteoclast differentiation factor and as a biomarker for osteoporosis or metastatic prostate cancer.. .
Osteoneurogen

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Immunomet Therapeutics Inc.

An improved belt system for body support

The present invention is a mechanical assembly for single point torque adjustment, an apparatus and method of use of an improved belt for body support and for assisting body during musculoskeletal activities like heavy lifting, kneeling, bending and walking. The belt employs the single point torque adjusting mechanical assembly with an adjustable hinge along with resilient means which stores potential energy when the user alters from a neutral position and may help the body to return to the neutral position.

Novel tricyclic calcium sensing receptor antogonists for the treatment of osteopososis

Novel tricyclic compounds of formula (i) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists.
Merck Sharp & Dohme Corp.

Furo[3,4-b]pyran compounds and pharmaceutical uses

Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited

Red light implants for treating osteoporosis

The irradiation may be carried out from a light source located inside the bone. The light may enter the bone via a transmitter located underneath the skin of the patient..

Beta-catenin

The invention relates to b-catenin, and to the use of compounds which can affect b-catenin translocation within the cell, for use in treating b-catenin/wnt-signaling-related disorders, such as osteoporosis, cancer or diabetes. The invention extends to pharmaceutical formulations and compositions comprising such compounds..
Ucl Business Plc

Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion

This invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like rna (shrna) compositions, such as microrna precursors (pre-mirna) and short interfering rnas (sirna), which are useful for treating human ageing related diseases, such as, but not limited, alzheimer's diseases, parkinson's diseases, osteoporosis, diabetes, and cancers.

Osteoporosis diagnostic support apparatus

Provided is an apparatus for measuring the thickness, roughness, and morphology index of the mandibular cortical bone using a dental panorama image to assist in the diagnosis of osteoporosis, wherein the thickness, roughness, and morphological index of the cortical bone is measured more accurately and the diagnosis of osteoporosis can be supported more accurately. An osteoporosis diagnostic support apparatus, wherein the apparatus has a contour extraction unit adapted to extract a mandibular contour from an image of a mandibular cortical bone photographed by a photographic apparatus adapted to photograph the mandibular cortical bone and surroundings thereof, a line segment extraction unit adapted to extract line segments from the image of the mandibular cortical bone photographed by the photographic apparatus; and a cortical bone thickness calculation unit adapted to calculate a thickness of the cortical bone based on the extracted mandibular contour and line segments..
Gifu University

Orexin-control of bone formation and loss

The use of orexin 1 receptor antagonists and/or orexin 2 receptor agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases..
The Board Of Regents Of The University Of Texas System

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis..
Merck Sharp & Dohme Corp.

Pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide y as active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide y as an active ingredient. The neuropeptide y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent.
Kyungpook National University Industry-academic Cooperation Foundation

Cartilage product

The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The present invention also relates to the cartilage product obtainable through said method.
Bioiberica, S.a.

Combination of lupeol acetate and curcumin used for the treatment or prevention of activated osteoclast precursor associated disorders

The present invention relates to synergistic combinations of lupeol acetate and curcumin at low dosage, and their use for the treatment or prevention of activated osteoclast precursor related diseases, including rheumatoid arthritis and osteoporosis.. .
National Yang-ming University

Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. Via injection, transplantation, or implantation) into a site of non-soft tissue (e.g.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis

The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis

The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc

A novel hormone that promotes bone resorption and uses thereof

The disclosure describes the use of anti-igfbp1 antibodies to inhibit the bone loss-inducing properties of fgf21. This can be applied in the context of fgf21 treatment for obesity and/or diabetes, or in menopause-induced bone loss, such as osteoporosis..
The Board Of Regents Of The University Of Texas System

Novel aromatic compound and use thereof

[wherein each substituent is as defined in the description], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or to treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.. .

Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited

Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, alzheimer's disease, parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided.
Concordia University



Osteoporosis topics:
  • Steoporosis
  • Osteoporosis
  • Breast Cancer
  • Dysfunction
  • Rheumatoid Arthritis
  • Endothelial Dysfunction
  • Endothelial
  • Nephropathy
  • Inflammation
  • Congestive Heart Failure
  • Hypertension
  • Bone Resorption
  • Resorption
  • Cardiovascular
  • Prostate Cancer


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Osteoporosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Osteoporosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.425

    file did exist - file did put2445

    5 - 1 - 51